CANNABICHROMENE / CBC & Cannabis studies completed
Overview
Science and Research
2012 - Study ~ Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice
2011 - Study ~ The endocannabinoid system and cancer: therapeutic implication.
2011 - Study ~ Phytocannabinoids for use in the treatment of cancer - Patent GB2478595 (A) ― 2011-09-14.
2011 - Study ~ Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.
2011 - Study ~ The intersection between cannabis and cancer in the United States.
2011 - Study ~ Non-psychoactive
cannabinoids modulate the descending pathway of antinociception in
anaesthetized rats through several mechanisms of action.
2011 - Study ~ Cannabinoids in children.
2010 - Study ~ Antidepressant-like effect of Delta(9)-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.
2009 - Study ~ Evaluation of Prevalent Phytocannabinoids in the Acetic Acid Model of Visceral Nociception.
2009 - Study ~ TRB3 links ER stress to autophagy in cannabinoid anti-tumoral action.
2008 - Study ~ Antibacterial cannabinoids from Cannabis sativa: a structure-activity study.1990 - Study ~ In vitro metabolism of cannabichromene in seven common laboratory animals
1989 - Study ~ Antiinflammatory and antimicrobial compounds and compositions
United States Patent 4837228
1989 - Study ~ Antiinflammatory and antimicrobial compounds and compositions
United States Patent 4837228
1984 - Study ~ Intraocular pressure, ocular toxicity and neurotoxicity after administration of delta 9-tetrahydrocannabinol or cannabichromene
1983 - Study ~ Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol.
1983 - Study - Allergenic properties of naturally occurring cannabinoids.
1982 - Study ~ Process for preparing cannabichromene.
1981 - Study - Biological activity of cannabichromene, its homologs and isomers.
1975 - Study ~ Constituents of Cannabis sativa L. VIII: Possible biological application of a new method to separate cannabidiol and cannabichromene.Similar Research
CANNABIDIOL / CBD / CHEMICAL COMPOSITION / THC - TETRAHYDROCANNABINOLAllergenic properties of naturally occurring cannabinoids.
Abstract
The guinea pig maximization test was used to determine the potential of seven cannabinoids to produce allergic contact dermatitis. delta 9-Tetrahydrocannabinol and cannabinol were found to be extreme (Grade V) sensitizers. Cannabidiol, delta 8-tetrahydrocannabinol, and cannabichromene were moderate (Grade III) sensitizers. Cannabigerol and cannabinol methyl ether were not sensitizers.
Most of the cannabinoids were found to be allergenically cross-reactive. Additionally, it was shown that the presence of a free 1'-hydroxyl group was required for sensitization, but not to elicit a response in sensitive animals.
Biological activity of cannabichromene, its homologs and isomers
J Clin Pharmacol. 1981 Aug-Sep;2
Abstract
Cannabichromene (CBC) is one of four major cannabinoids in Cannabis sativa L. and is the second most abundant cannabinoid in drug-type cannabis.
Cannabichromene and some of its homologs, analogs, and isomers were evaluated for antiinflammatory, antibacterial, and antifungal activity. Antiinflammatory activity was evaluated by the carrageenan-induced rat paw edema and the erythrocyte membrane stabilization method.
In both tests, CBC was superior to phenylbutazone. Antibacterial activity of CBC and its isomers and homologs was evaluated using gram-positive, gram-negative, and acid-fast bacteria.
Antifungal activity was evaluated using yeast-like and filamentous fungi and a dermatophyte. Antibacterial activity was strong, and the antifungal activity was mild to moderate.